Table 1 Results of the use of PTNS in OAB Patients

Klingler HC

2000 [13]

N/A

15

10

67

N

Urodynamic and clinical

3

<10 voids/day <2voids/night PadTest (g) 10

73

N/A

N

Govier FE

2001 [14]

N/A

47

71

N

Urodynamic

2-3

25% reduction in mean daytime voiding frequency

90

57.4 (24–80)

Y

van Balken MR

2001 [15]

N/A

37

22

59

N

Clinical

2-3

Request for continued chronice treatment

73

52.5 (23–74)

Y

Vandonink V

2003 [16]

N/A

35

24

69

N

Clinical

2-3

Continuing treatment

71

57 (29–82)

Y

Vandonink V

2003 [17]

N/A

60

34

57

N

Urodynamic

2-3

50% reduction

Y

Peters KM

2009 [20]

Tolterodine

44

35

80

42

23

55

0.01

Y

Clinical

2-3

Improvemtn for cure in 79.5% compared to 54.8% in the tolterodine arm

96

92

57.5

58.2

Y

Peters KM

2010 [22]

Sham

110

60

55

110

23

21

<0.001

Y

Clinical

1

Improvement in overall bladder symptoms

78

80

62.5

60.2

N

Finazzi-Agro E

2010 [23]

Placebo

17

12

71

15

0

0

<0.001

Y

Clinical

1

50% reduction

100

100

44.9

45.5

N

Amarenco G

2003 [38]

N/A

44

22

50

N

Clinical

1

66

53.3

N

van Der pal F

2005 [26]

N/A

11

11

100

N

Clinical

Improvement in overall bladder symptoms

54.5

51 (33–66)

N

Karademir K

2005 [18]

Oxybutynin + PTNS

21

13

62

22

18

82

<0.0001

Y

Clinical

Improvement in overall bladder symptoms

Y

de Séze M

2011 [45]

N/A

70

58

82.8

N

Urodynamic and clinical

Improvement in 82.6% and 83.3% of the patients on day 30 and day 90 regarding symptoms and QoL

N

van Balken MR

2006 [44, 47]

N/A

132

43 O/68 S

32,6 O/51,5 S

N

Clinical

Improvement QoL

61.3

53 (21–82)

N

Nuhoglu B

2005 [19]

N/A

35

19

54

N

Urodynamic and clinical

Improvement Urgency and QoL

100

47.3 (35–57)